Cardio-oncology & otherCohort study
Clonal Hematopoiesis and Risk of Heart Failure After Autologous Hematopoietic Cell Transplantation for Lymphoma
- Retrospective cohort study
- single-centre
Authors' conclusion
CHIP was highly prevalent and associated with risk for HF and nonrelapse mortality after HCT.
Study context
- Population
- Patients undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma, City of Hope Comprehensive Cancer Center, 2010–2016
- Participants
- 861 patients
- Exposure
- Clonal hematopoiesis of indeterminate potential (CHIP) vs no CHIP
- Outcome
- Cumulative incidence of de novo HF
- Follow-up
- 5 years
Main finding
As reported in the abstract
Subdistribution hazard ratio
2.48
95% CI 1.32–4.68
P < 0.001
By group
CHIP vs No CHIP
sHR 2.48 (95% CI 1.32–4.68); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values | subdistribution HR (95% CI) | P value | |
|---|---|---|---|---|
| Nonrelapse mortality | 5.37 (2.34–12.35) | |||
| 0.050.21520Subdistribution hazard ratio (log scale) |
| Outcome | Values | Estimate | P value |
|---|---|---|---|
| 5-year HF incidence by variant allele frequency | 0-2% 4.7% · 2-10% 11.7% · >10% 18.5% | ||
| Overall survival after HCT | CHIP 63.4% · No CHIP 80.3% | P < 0.001 |
- 5-year heart failure (HF) incidence by variant allele frequency: P < 0.001
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clonal Hematopoiesis and Risk of Heart Failure After Autologous Hematopoietic Cell Transplantation for Lymphoma. JACC CardioOncol. Published 3 December 2024. doi:10.1016/j.jaccao.2024.10.006
Summarised from the published abstract; every number is checked against it